Foamix CEO Dr. Dov Tamarkin to Present "FOAM IS THE FUTURE VEHICLE FOR COSMECEUTICAL PRODUCTS" at HBA on September 27^th from 2:15 pm – 4:45 pm

Ness Ziona, Israel, September 12, 2005 --- Foamix ( www.foamix.co.il)announced today that it will be exhibiting at the Health and Beauty America Conference at the Jacob K. Javits Convention Center, at 655 West 34th Street in New York, NY, September 27-29, 2005. Attendees are invited to visit the team at booth number 1051 for a briefing and demonstration of Foamix’s Cosmetic Foams.

Foamix Emulsion-based Cosmetic Foams mix oil and water to create a brilliant, patent-pending, new delivery system perfect for dispensing any cosmetic. Foamix’s Cosmetic Foams are stable, highly absorbent, light and luxuriously creamy. They are stable, spread easily, dissolve quickly and leave a clean, fresh feeling. Foamix’s Cosmetic Foams enable scents to last longer on the skin and can employ any type of oil, in its proprietary drip-free oil formula. Foamix’s Cosmetic Foams are designed for cosmetic companies poised to enhance the face of skin care.

“Foam products are preferred by customers and known to generate premium returns. Our goal at the HBA is to establish partnerships with cosmetic companies keen on delivering their products in an alcohol-free, state-of-the-art foam delivery system. We look forward to seeing you in NY,” said Foamix CEO Dr. Dov Tamarkin.

Foamix also announced today that CEO Dr. Dov Tamarkin is scheduled to present at HBA on Tuesday, September 27, 2005, 2:15pm - 4:45pm, as part of the PDMC 1 Master Class - NEW DEVELOPMENTS IN DELIVERY SYSTEMS track. The title of Dr. Tamarkin’s presentation: FOAM IS THE FUTURE VEHICLE FOR COSMECEUTICAL PRODUCTS. Please refer to the program guide for an exact location.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, non-flammable, stable foam products for prescription, Over-the-Counter and cosmetic uses. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The Company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing and clinical supplies. The Company was founded in January 2003 by CEO Dr. Dov Tamarkin, COO Mr. Meir Eini and Chief Technology Officer Dr. Doron Friedman. The Company employs 24 people and has 22 patents pending. In addition, Foamix recently received three U.S. patent approvals for its OilGel™ topical delivery platform. Foamix Ltd. is a pre-IPO, privately held company, currently looking to establish partnerships with likeminded cosmetic companies.

For additional information: Marjie Hadad, Media Liaison, Marjie@foamix.co.il or +972-54-536-5220.